Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senl_B19 CAR-T in R/R B-ALL
NCT07244406Phase 2Recruiting
- Sponsor
- Senlang Bio
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SENL-B19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Senlang Bio. Primary endpoint: Objective Response Rate at 3 months. Started Jan 2025; status: recruiting.
02
Drugs
SENL-B19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07244406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244406.